CNS Drug Development

ABVC BioPharma Strengthens Investment in AiBtl BioPharma with Equity Conversion and Up to $20 Million Commitment

ABVC BioPharma Strengthens Investment in AiBtl BioPharma with Equity Conversion and Up to $20 Million Commitment

ABVC BioPharma's strategic equity conversion and investment in AiBtl BioPharma underscores its commitment to advancing CNS drug candidates and leveraging a capital-light strategy for future growth.

June 24, 2025
Clinilabs Strengthens Leadership Team to Drive CNS Drug Development Growth

Clinilabs Strengthens Leadership Team to Drive CNS Drug Development Growth

Clinilabs, LLC enhances its executive team with the appointment of David Hagerman as CFO and Jeanine Falinski as SVP of Commercial Development, signaling a strategic push to bolster its position in CNS drug and medical technology development.

June 4, 2025